Jacobs Levy Equity Management, Inc Cardiff Oncology, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $24.2 Billion
- Q2 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 92,269 shares of CRDF stock, worth $224,213. This represents 0.0% of its overall portfolio holdings.
Number of Shares
92,269
Previous 396,118
76.71%
Holding current value
$224,213
Previous $1.24 Million
76.67%
% of portfolio
0.0%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding CRDF
# of Institutions
126Shares Held
25.8MCall Options Held
1.01MPut Options Held
293K-
Vanguard Group Inc Valley Forge, PA3.73MShares$9.06 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.63MShares$6.39 Million0.0% of portfolio
-
Blair William & CO Chicago, IL2.52MShares$6.13 Million0.02% of portfolio
-
Laurion Capital Management LP New York, NY1.8MShares$4.37 Million0.11% of portfolio
-
Geode Capital Management, LLC Boston, MA1.5MShares$3.64 Million0.0% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $105M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...